At a glance
- Originator GlaxoSmithKline
- Class Benzoxazoles; Obesity therapies; Urea compounds
- Mechanism of Action Orexin receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Obesity
Most Recent Events
- 17 Dec 2003 No development reported - Preclinical for Obesity in United Kingdom (unspecified route)
- 24 Jan 2001 SmithKline Beecham has merged with Glaxo Wellcome to form GlaxoSmithKline
- 06 Dec 2000 New profile